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a b s t r a c t
Intracellular cyclic nucleotides are eliminated by phosphodiesterases (PDEs) and by ATP Binding cassette
transporters such as ABCC4 and ABCC5. PDE5 and ABCC5 have similar afﬁnity for cGMP whereas ABCC5
has much higher afﬁnity for cGMP compared with cAMP. Since the substrate (cGMP) is identical for these
two eliminatory processes it is conceivable that various PDE inhibitors also modulate ABCC5-transport.
Cyclic GMP is also transported by ABBC4 but the afﬁnity is much lower with a Km 50–100 times higher
than for that of ABBCC5. The present study aimed to determine Ki-values for speciﬁc or relative speciﬁc
PDE5 inhibitors (vardenaﬁl, tadalaﬁl, zaprinast and dipyridamole) and the non-speciﬁc PDE inhibitors
(IBMX, caffeine and theophylline) for ABCC5 andABCC4 transport. The transport of [3H]-cGMP (2 mM)
was concentration-dependently inhibited with the following Ki-values: vardenaﬁl (0.62 mM), tadalaﬁl
(14.1 mM), zaprinast (0.68 mM) and dipyridamole (1.2 mM), IBMX (10 mM), caffeine (48 mM) and theophyl-
line (69 mM). The Ki-values for the inhibition of the [
3H]-cAMP (2 mM) transport were: vardenaﬁl
(3.4 mM), tadalaﬁl (194 mM), zaprinast (2.8 mM), dipyridamole (5.5 mM), IBMX (16 mM), caffeine (41 mM)
and theophylline (85 mM). The speciﬁcity for ABCC5 we deﬁned as ratio between Ki-values for inhibition
of [3H]-cGMP and [3H]-cAMP transport. Tadalaﬁl showed the highest speciﬁcity (Ki-ratio: 0.073) and
caffeine the lowest (Ki-ratio: 1.2).
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
The major pharmacotherapeutic progress during the last 50
years includes drugs which modulate signalling systems. One
example is the drugs that inﬂuence cyclic nucleotide biokinetics
with effects on the balance between synthesis and elimination
(Beavo and Brunton, 2002). The cellular elimination of cyclic
nucleotides comprises PDEs responsible for biotransformation
and ABC-transporters which account for the cellular efﬂux of
unmodiﬁed molecule. In humans 11 PDE families with different
tissue distribution and substrate speciﬁcity exist (Francis et al.,
2011). Signiﬁcant progress has been made in developing speciﬁc
inhibitors of PDEs to obtain more selective effects and minimise
adverse effects. The feasibility of these enzymes as drug targets is
exempliﬁed by the commercial and clinical successes of the
erectile dysfunction drugs, sildenaﬁl, tadalaﬁl and vardenaﬁl.
However, still non-speciﬁc PDE inhibitors are in clinical use
(Savai et al., 2010).
During the last decades the mechanisms that regulate the
intracellular levels of cGMP have been clariﬁed. A ﬁnely tuned
balance between synthesis, degradation and efﬂux with compart-
mentalisation of the biokinetics components (cyclases, phosphodies-
terases and efﬂux pumps) exist (Cheepala et al., 2013). The signature
substance of speciﬁc PDE5 inhibitors, sildenaﬁl, prevents the high
afﬁnity cellular cGMP efﬂux (Sundkvist et al., 2002) by inhibition of
ABCC5 (Jedlitschky et al., 2000). Cyclic GMP is transported by ABCC5
with high afﬁnity (Km-valueE2 mM) (Jedlitschky et al., 2000), and
clearly higher than ABCC4-mediated transport. It is possible that an
early report of high afﬁnity (KmE10 mM) might have overestimated
the ABCC4 afﬁnity for cGMP by limiting the concentrations to 25 mM
(Chen et al., 2001). Much higher Km-values have been reported:
170–180 mM (Klokouzas et al., 2003; van Aubel et al., 2005) and a Ki-
value of 280 mM (Orvoll et al., 2013). In agreement, Jedlitschky et al.
(2000) reported that inhibition of ABCC5-mediated cGMP transport
of cAMP was detected only at concentrations above 100 mM. On the
other hand ABCC4 has a preference for cAMP in low concentrations
with Km-values 30–45 mM (Chen et al., 2001; Orvoll et al., 2013).
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Several reports exist on interactions between PDE inhibitors and
ABC-transporters; inhibition of ABCC5 by zaprinast (Jedlitschky
et al., 2000), ABCB1 by sildenaﬁl, vardenaﬁl and tadalaﬁl (Shi
et al., 2011; Ding et al., 2011) and ABCG2 by sildenaﬁl (Shi et al.,
2011). In the present paper the term selective has been used to
distinguish between molecular targets (i.e. PDEs versus ABCC
transporters) and speciﬁcity to distinguish between the individual
enzymes or transporters within the same family. Recently, we
reported that sildenaﬁl and sildenaﬁl analogues inhibit high afﬁnity
[3H]-cGMP transport (Sager et al., 2012) and that, at least some of
these, exhibit a speciﬁcity in their inhibition of ABCC4 and ABCC5
(Orvoll et al., 2013). To extend these observations the present study
aimed to obtain Ki-values of speciﬁc and non-speciﬁc PDE inhibitors
of ABCC4 and ABCC5.
2. Materials and methods
2.1. Chemicals
Cyclic GMP, cyclic AMP, zaprinast, dipyridamole, theophylline,
theobromine, caffeine, IBMX (3-isobutyl-1-methylxanthine), ATP
magnesium, acetyl thiocoline chloride and 5,50-dithiobis-(2-nitro-
benzoic acid) were purchased from Sigma-Aldrich (Schnelldorf,
Germany), tadalaﬁl from Toronto Research Chemicals Inc. (Ontario,
Canada), [3H]-cGMP and [3H]-cAMP from Perkin Elmer Inc. (Boston,
MA, USA). Vardenaﬁl was a gift from Bayer Health Care AG
(Leverkusen, Germany). Other chemicals were of analytical grade.
2.2. Preparation of inside out vesicles
Fresh human EDTA blood was obtained from healthy donors
(Department of laboratory medicine, University hospital of North
Norway). The blood cells were separated from plasma by centri-
fugation and washed with 5 mM Tris–HCl, 113 mM KCl (pH 8.1)
three times before lysis. The cells were lysed in 10 volumes of
5 mM Tris–HCl, 0.5 mM EGTA, 4 mM KCl (pH 8.1) and washed in
the same buffer (20.000g for 20 min) until ghosts were milky
white. Inside-out vesicles were prepared using a modiﬁcation of
the procedure originally described by Steck et al. (1970). The
membrane vesiculation was initiated by adding 39 volumes of a
hypertonic buffer (500 mM Tris–HCl, pH 8.2) to one volume of cell
suspension and this process was completed after several hours. All
the steps above were performed at 2–4 1C. After centrifugation the
suspension was forced through a 27 gauge syringe needle to
enhance homogenisation of the membranes. Inside-out vesicles
were separated from right side out vesicles and ghosts by ultra-
centrifugation (100.000g) overnight using a density gradient from
1.048 g/ml to 1.146 g/ml (Histodenz, Sigma-Aldrich, Schnelldorf,
Germany) in 5 mM Tris, 3 mM KCl and 0.3 mM EGTA. The upper-
most band was collected, washed and resuspended in 1.47 mM
KH2PO4, 81 mM K2HPO4 and 140 mM KCl (pH 7.6). Sidedness was
veriﬁed using acetylcholinesterase accessibility with small mod-
iﬁcations of the original method (Ellman et al., 1961).
2.3. Transport assay
Transport assays were performed by incubating the inside-out
vesicles at 371C with or without 2.0 mM ATP at various inhibitor
concentrations. All assays were carried out in triplicates. Inhibition
assays for transport of 2 μM [3H]-cAMP or 2 μM [3H]-cGMP were
performed for dipyridamole (10 nM–1 mM), vardenaﬁl (1 nM–1 mM),
tadalaﬁl (1 nM–100 μM), IBMX (1 nM–1mM), zaprinast (1 nM–
100 μM), caffeine (10 nM–1 mM), theophylline (10 nM–1 mM), theo-
bromine (100 mM). After 60 min incubation in the presence of the
appropriate inhibitor the transport was stopped by adding ice cold
buffer with pH 7.6 (1.47 mM KH2PO4, 8.1 mM K2HPO4, 140 mM KCl).
The inside-out vesicles suspension was ﬁltered and washed with the
use of nitrocellulose membranes (0.22 μm GSWP, Millipore, Billerica,
MA) and the ﬁlters with inside-out vesicles were dissolved in
ethylene acetate and the radioactivity was quantiﬁed (Packard 1900
TR Liquid Scintillation analyser), after addition of scintillation ﬂuid
(Ultima Gold XR, Packard, Groningen, The Netherlands).
2.4. Data analysis
The IC50 values were determined according to Chou (1976).
These data were transformed to Ki-values according to Cheng and
Prusoff (1973). Substrate concentration was 2 mM for both cyclic
nucleotides whereas the Km-values used were 2.6 mM and 30.8 mM
for cGMP and cAMP, respectively, based on recently reported
values (Orvoll et al., 2013).
Fig. 1. Structures of speciﬁc PDE5 inhibitors (panel A), assumed speciﬁc PDE5 inhibitors (panel B) and non-speciﬁc PDE inhibitors (panel C).
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3. Results
3.1. Vardenaﬁl, tadalaﬁl, zaprinast, dipyridamole and cyclic
nucleotide efﬂux
The effect of PDE5 inhibitors on high afﬁnity ATP-dependent cyclic
nucleotide transport were previously characterised in the model with
human erythrocyte inside-out vesicles for cGMP with sildenaﬁl and
zaprinast (Sundkvist et al., 2002) and for cAMP with sildenaﬁl (Orvoll
et al., 2013). This model was employed in the present study to
compare the potency of the PDE5 inhibitors vardenaﬁl, tadalaﬁl,
zaprinast and dipyridamole (Fig. 1 panel A and panel B). Fig. 2 panel
A and Table 1 show the order of potency in [3H]-cGMP transport
inhibition: vardenaﬁlEzaprinast4dipyridamole»tadalaﬁl. The trans-
port of [3H]-cAMP was inhibited by somewhat different order of
potency: zaprinastZvardenaﬁl 4dipyridamole»tadalaﬁl (Fig. 2 panel
B and Table 1). The ratio between Ki for [3H]-cGMP and [3H]-cAMP
transport (Ki-ratio) shows the ability to discriminate between ABCC5
and ABCC4. The speciﬁcity towards ABCC5 showed the following
order: tadalaﬁl»vardenaﬁlZdipyridamoleZzaprinast (Table 1).
3.2. IBMX, caffeine, theophylline and cyclic nucleotide efﬂux
In order to compare afﬁnity and speciﬁcity of non-speciﬁc
PDE inhibitors IBMX, caffeine and theophylline were used in
the transport assays. These compounds gave a concentration-
dependent inhibition of the radiolabelled cGMP (Fig. 3 panel A)
and cAMP (Fig. 3 panel B). The order of potency in [3H]-cGMP
transport inhibition was IBMX»caffeine4theophylline and for
[3H]-cAMP transport inhibition: IBMX4caffeine4theophylline
(Table 2). The speciﬁcity for ABCC5 expressed as Ki-ratio was
IBMX4theophylline4caffeine. In the introductory screening stu-
dies theobromine was included. The reduction of [3H]-cGMP and
[3H]-cAMP transport with 100 mM of theobromine was 55.074%
and 51.273.2%, respectively.
4. Discussion
Cyclic nucleotide phosphodiesterases have recently gained an
increasing pharmaceutical interest, due to structure-based design
of novel speciﬁc inhibitors, to the increasing understanding of the
roles of individual PDEs, and to the development of reﬁned
strategies to target individual PDE variants (Maurice et al., 2014).
Speciﬁc inhibitors of PDEs have been developed, and sildenaﬁl was
established as a speciﬁc PDE5 inhibitor with IC50-values of 4–10 nM
and the subsequent substances like vardenaﬁl and tadalaﬁl had
IC50-values of 0.14–1 nM and 1.8–10 nM, respectively (Francis et al.,
2011). In this work we have used the term speciﬁc to distinguish
between members of the PDE-family and members of the ABC-
transporter subfamily C. To differ between entirely different mole-
cular targets such as PDEs and ABC-transporters, we have employed
the term selectivity.
We have employed human erythrocytes which express both
ABCC4 (Klokouzas et al., 2003; Wu et al., 2005; de Wolf et al.,
2007; Rius et al., 2008) and ABCC5 (Jedlitschky et al., 2000;
Klokouzas et al., 2003; Wu et al., 2005; de Wolf et al., 2007).
Cyclic GMP is transported out with high afﬁnity by ABCC5
(Jedlitschky et al., 2000) and cAMP by ABCC4 with lower, but still
high afﬁnity (Chen et al., 2001). The impact of ABCC4 on cellular
cAMP efﬂux was recently conﬁrmed (Copsel et al., 2011). The high
afﬁnity efﬂux of these endogenous substances is speciﬁc since they
are unable to mutually interact in physiologic concentrations
(Orvoll et al., 2013). The speciﬁcity of ABCC4 and ABCC5 is
regulated by the cAMP and cGMP in a concentration dependent
manner (Orvoll et al., 2013). Apparently the transporters exist in a
speciﬁc high afﬁnity state that switch into a “multiorganic anion
transporter state” at higher concentrations with similar and low
afﬁnity for cAMP and cGMP (Wielinga et al., 2003). The repor-
ted low afﬁnity transport Km-values for cAMP are 300–400 mM
(Jedlitschky et al., 2000; Orvoll et al., 2013) and for cGMP (150–
650 mM) (Jedlitschky et al., 2000; Klokouzas et al., 2003; van Aubel
et al., 2005; Wittgen et al., 2012). In the inside-out vesicles model
of human erythrocytes the ATP-dependent transport of cyclic
nucleotides in low concentrations mainly represents speciﬁc and
high afﬁnity transport of cAMP by ABCC4 and cGMP by ABCC5.
Fig. 2. Inhibition of radiolabelled cyclic nucleotides by speciﬁc PDE5 inhibitors vardenaﬁl (▲) and tadalaﬁl (▼) and assumed speciﬁc PDE5 inhibitors zaprinast (●) and
dipyridamole (x). Panel A: [3H]-cGMP and panel B: [3H]-cAMP.
Table 1
Ki-values for inhibition of [3H]-cGMP and [3H]-cAMP for the speciﬁc PDE5
inhibitors vardenaﬁl and tadalaﬁl and the previously assumed speciﬁc PDE5
inhibitors zaprinast and dipyridamole. IC50-values were determined according to
Chou (1976) and Ki was obtained according to Cheng and Prusoff (1973). The
speciﬁcity for ABCC5 is expressed as a ratio between Ki for cGMP and cAMP
transport (Ki-ratio).
Inhibitor Ki (mM)a Ki-ratio
[3H]-cGMP [3H]-cAMP
Tadalaﬁl 14.171.6 194719 0.073
Vardenaﬁl 0.6270.09 3.470.07 0.18
Dipyridamole 1.270.15 5.570.29 0.21
Zaprinast 0.6870.06 2.870.25 0.24
a Results are presented as mean7S.E.M.
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Table 3 shows Ki-values obtained in the present study and
reported in or calculated based on data in previous publications
for cGMP transport by ABCC5 and cGMP hydrolysis by PDE5.
Sildenaﬁl inhibits ABCC5-mediated cGMP efﬂux with a Ki of
0.7 mM (Jedlitschky et al., 2000). Later observations suggested that
the afﬁnity was somewhat less with Ki-values of 1.2–3.6 mM
(Sundkvist et al., 2002; Sager et al., 2012). However, a 100–1000
fold lower afﬁnity for ABCC5 shows that sildenaﬁl has a distinct
selectivity for PDE5. This also applies to vardenaﬁl and tadalaﬁl but
the present study showed that vardenaﬁl (Ki¼0.6 mM) was mark-
edly stronger inhibitor than tadalaﬁl (Ki¼14.1 mM) of ABCC5-
mediated cGMP transport.
It has been a common belief that zaprinast (Francis et al., 2011)
and dipyridamole (Lugnier, 2006) were speciﬁc PDE5 inhibitors
but this notion should be reconsidered. Zaprinast also inhibits
PDE1 and PDE6, inhibits adenylyl cyclase and modulate intracel-
lular calcium (Francis et al., 2011). However, it is interesting that a
similar afﬁnity exist for the inhibition by zaprinast of PDE5 (Ki of
0.13–0.8 mM) (Francis et al., 2011) and ABCC5 with Ki of 0.49 mM
(Sundkvist et al., 2002) and 0.64 mM in present study. The IC50
values for dipyridamole inhibition of cAMP–PDE and cGMP–PDE
were 13 and 0.3 mM, respectively (Lugnier et al., 1986). Later,
dipyridamole was reported to interact with PDE2, PDE4, PDE6;
PDE7, PDE8, PDE10 and PDE11 (Lugnier, 2006; Bender and Beavo,
2006). Other reported effects are inhibition of nucleoside trans-
porters in erythrocytes (Schaper, 2005) and inhibition of ABCC5
mediated cGMP transport with Ki of 0.35 mM (Sundkvist et al.,
2002) and 1.2 mM in the present study. The dipyridamole Ki-values
for PDE5 and ABCC5 are similar.
In the present work we studied the speciﬁcity of high afﬁnity
transport. Whilst tadalaﬁl displayed a lower inhibitory effect on
the ABCC transporters, it had a much higher speciﬁcity for ABCC5
compared to ABCC4 (Ki-ratioE0.07). For vardenaﬁl, dipyridamole
and zaprinast the ABCC5 speciﬁcity existed with respective ratios
of 0.18, 0.21 and 0.24. In comparison, the Ki-ratio for sildenaﬁl was
0.45, calculated from previous reported IC50 values (Orvoll et al.,
2013). However, the ABC-transporter speciﬁcity is a challenge
illustrated by the facts that sildenaﬁl, in addition to ABCC4 and
ABCC5, inhibits ABCB1- and ABCG2-transport (Shi et al., 2011),
vardenaﬁl and tadalaﬁl interact with ABCB1 (Ding et al., 2011). On
the other hand, this is also the hallmark of this multiorganic anion
transporter family.
IBMX is a non-speciﬁc inhibitor of cyclic nucleotide PDEs with a
Ki of 2–10 mM for PDE5 (Francis et al., 2011). Similar inhibition of
high afﬁnity cyclic nucleotide transport was evident with Ki-values
of 10 and 16 mM for [3H]-cGMP and [3H]-cAMP, respectively. This
indicates that IBMX tends to be ABCC5-speciﬁc. Caffeine and
theophylline show little selectivity among PDEs 1–11 with IC50
values ranging from 100 to 1000 mM (Francis et al., 2011). These
substances appear to be non-selective (PDE5 versus ABCC4/5) and
non-speciﬁc (ABCC5 versus ABCC4).
Fig. 3. Inhibition of radiolabelled cyclic nucleotides by non-speciﬁc PDE inhibitors IBMX (x), caffeine (■) and theophylline (▲). Panel A: [3H]-cGMP and panel B: [3H]-cAMP.
Table 2
Ki-values for inhibition of [3H]-cGMP and [3H]-cAMP for the non-speciﬁc PDE5
inhibitors dipyridamole, IBMX, theophylline and caffeine. IC50-values were deter-
mined according to Chou (1976) and Ki was obtained according to Cheng and
Prusoff (1973). The speciﬁcity for ABCC5 is expressed as a ratio between Ki for
cGMP and cAMP transport (Ki-ratio).
Inhibitor Ki (mM)a Ki-ratio
[3H]-cGMP [3H]-cAMP
IBMX 10.070.8 16.271.3 0.62
Caffeine 48.271.2 40.772.9 1.2
Theophylline 68.771.5 85.472.6 0.80
a Results are presented as mean7S.E.M.
Table 3
Ki-values for cGMP transport by ABCC5 and cGMP hydrolysis by PDE5. Present
results and reported values. Most studies report IC50-values for PDE5 inhibition
without substrate concentration and Km value for cGMP hydrolysis.
ABCC5 PDE5
Ki (mM) Ki (mM)
Sildenaﬁl 0.24 (Jedlitschky et al, 2000) 0.0020 (Moreland et al., 1998)
3.6 (Sundkvist et al, 2002) 0.0027 (Ballard et al., 1998)a
1.2 (Sager et al, 2012) 0.001 (Turko et al., 1999)
0.0147(Kim et al., 2001)
0.0022(Wang et al., 2001)a
Vardenaﬁl 0.62 0.0045 (Kim et al, 2001)
0.0023 (Cahill et al., 2012)
Tadalaﬁl 14.1 0.0019 (Cahill et al, 2012)
Zaprinast 0.68 0.65 (Ballard et al, 1998)a
0.35 (Sundkvist et al, 2002) 0.25 (Moreland et al, 1998)
0.13 (Turko et al, 1999)
0.22(Wang et al, 2001)a
Dipyridamole 1.2 0.46 (Wang et al, 2001)a
0.35 (Sundkvist et al, 2002)
IBMX 10 3.6 (Wang et al, 2001)a
Caffeine 48 250–1000 (Francis et al, 2011)b
Theophylline 69 250–1000 (Francis et al, 2011)b
a Ki calculated based on IC50 according to Cheng and Prusoff (1973).
b Ki estimated based on relative potency to vardenaﬁl.
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In addition to the inhibition of PDEs and ABC-transporters,
theophylline and caffeine antagonise the effects of adenosine on
adenosine receptors, where they have the modest afﬁnity with
Ki-values 1–25 mM and 10–100 mM for theophylline and caffeine,
respectively (Muller and Jacobson, 2011). The present study shows
afﬁnities of caffeine for ABCC4 and ABCC5 of similar magnitude as
for the adenosine receptors. The future will show whether this
observation adds ABC-transporters to the list of potential mole-
cular targets for caffeine. Plasma caffeine levels 8 h after ingestion
(100 mg) were reported to be 10–15 mM (Tanaka et al., 2014) but
intracellular concentrations were not reported. Caffeine, a methyl-
xanthine, enters the brain by both simple diffusion and saturable,
carrier-mediated transport (McCall et al., 1982) and interacts with
equilibrative nucleoside transporter transporters (ENT), more
recently classiﬁed as SLC29 (Lang et al., 2004). Obvious candidates
for caffeine transport are SLC28 and SLC29 (Cano-Soldado and
Pastor-Anglada, 2012) but caffeine is not mentioned as substrate or
inhibitor for these transporters in the Concise Guide to Pharma-
cology 2013/14: Transporters (Alexander et al., 2013). However,
the caffeine inhibition of ABCC4 and ABCC5, localised at the blood
side (Hartz and Bauer, 2011), will diminish substrate efﬂux from
the brain, including caffeine itself.
In conclusion, PDE5 speciﬁc inhibitors such as sildenaﬁl, varde-
naﬁl and tadalaﬁl are selective since afﬁnity for ABCC4/5 is exceed-
ingly lower compared to that of PDE5. The present data also
demonstrate speciﬁcity towards ABCC5 compared to ABCC4. Finally,
we show that caffeine and theophylline inhibit ABCC4/5 transport
with Ki-values that are relevant after intake of these substances and
apparently with higher afﬁnity than inhibition of PDE5 (Table 3).
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